Guardant Health

For the fourth year in a row, we’re proud to share we’ve been named to Computerworld’s Best Places to Work in IT list, ranking 18th among midsize organizations for 2026. This recognition belongs to our global technology teams, whose work continues to shape our culture and move our mission forward every day. More details: https://bit.ly/4oOLbyI #BestPlacesIT

Expanding access to cancer clinical trials starts with smarter connections.   Today, we’re announcing a new collaboration with Trial Library that unites our large-scale genomic data and their AI-powered matching and navigation platform to help more patients, including those in representative and underserved communities, reach the right precision oncology clinical trials.   More details: https://lnkd.in/e_x9XsSw

In a new look at the future of cancer prevention, Fast Company highlights how Shield™ builds on a decade of innovation to make colorectal cancer screening easier for patients to complete — showcasing how a simple blood draw could improve early detection and why it was named to Fast Company’s World Changing Ideas list for 2025.

Introducing FPG 360, one of Italy’s first in-house liquid biopsy testing services at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome. Powered by our Guardant360® CDx technology, this new service expands access to precision oncology diagnostics and supports both routine care and clinical research. “This collaboration of public healthcare and private innovation enables broader access for blood-based cancer profiling and genomic insights,” underscored our Co-CEO Helmy Eltoukhy. “Bringing our liquid biopsy technology to one of Europe’s leading cancer centers is another step in our mission to help clinicians worldwide create more personalized treatment plans and improve outcomes.”

We look forward to sharing new data next week at #SABCS25, where we will present 14 abstracts demonstrating the power of multiomic liquid biopsy testing in predicting outcomes and tailoring treatment for patients with early and metastatic breast cancer. 📍 Stop by Booth 942 to learn more. Additional details: https://lnkd.in/g-kvmx36

Shield™ is poised to transform colorectal cancer screening — yet millions remain unable to take advantage of this breakthrough. The science is here. The need is clear. But federal screening guidelines remain out of step with the tools that can help close the country’s screening gap. In a new piece for The Hill, our Co-CEO AmirAli Talasaz breaks down what's slowing adoption — and what it will take to ensure Shield reaches the millions who could benefit. Read more: https://lnkd.in/eDCtJjJr

Today, we welcomed Guardant Health’s Co-Founder and co-CEO, Helmy Eltoukhy, and the team to The Royal Marsden, Chelsea. Guardant Health is a leading industry pioneer in liquid biopsy testing and industry partner of The Royal Marsden. Our Marsden360 ctDNA test was developed by Guardant Health and implemented by The Royal Marsden’s Clinical Genomics team through an innovative tech transfer. Marsden360 is a minimally invasive liquid biopsy test, taken from a simple blood sample, that detects genetic changes in tiny amounts of circulating tumour DNA in the blood and is an example of how genomics is delivering innovation in cancer testing. The session was chaired by Professor Sanjay Popat, Consultant Medical Oncologist, Head of the Lung Unit, The Royal Marsden. At the meeting, the team from Guardant Health were joined by several consultants and clinical genomics leaders at The Royal Marsden to discuss future partnership opportunities and reflect on the achievements of our ongoing collaboration. Our long-term partnership with Guardant Health is a great example of how working with industry leaders is helping us to achieve our ambitions for genomics innovation in the UK. Helping to improve the lives of our patients now and in the future.  Find out more about Marsden360 and our work in clinical genomics: https://brnw.ch/21wXFOW

As molecular residual disease (MRD) testing becomes more integrated into clinical development, understanding the differences between tissue-informed and tissue-free approaches is essential to optimizing trial design and accelerating decision-making.   Join Arielle Medford, MD, and Derek Dustin, PhD, at 2PM PT on Monday, November 24, for an exclusive webinar exploring the latest advancements in MRD testing for breast cancer, including how tissue-free, methylation-based assays are enabling earlier detection of recurrence and improving trial efficiency.   Register: https://lnkd.in/e_tpN65P

A new era of data collaboration begins today:   We’re excited to announce the launch of the Single Namespace Working Group (SNS)—a 34-member consortium uniting leading technology, healthcare, and research organizations to establish the first open standard for exabyte-scale data interoperability. Together, we’re setting a new benchmark for secure, AI-ready data access that will accelerate insights and innovation across the global scientific community. Details: https://lnkd.in/exEUSt8q

Guardant Reveal® has officially expanded beyond MRD detection to include therapy response monitoring for patients with advanced solid tumors. With this expansion, oncologists now have a single, tissue-free solution that empowers confident, ctDNA-guided decisions across the care continuum. Powered by our Guardant Infinity™ Smart Platform, Guardant Reveal quantifies cancer with molecular precision, providing highly sensitive results in just 7 days. More details: https://lnkd.in/dkR_bwga